Exelixis | EXEL - Ebit


Exelixis reported $251.34M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Amgen USD 3.83B 130M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 3.56B 90M Mar/2026
Cytokinetics USD -181.23M 2.86M Mar/2026
Eisai JPY -10.31B 30.35B Mar/2026
Eli Lilly USD 9.78B 792M Mar/2026
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Exelixis USD 251.34M 15.43M Mar/2026
Genmab DKK 260M 199M Dec/2025
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
Incyte USD 344.17M 39.71M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
MacroGenics USD -12.1M 32.26M Dec/2025
Merck USD -1.88B 8.12B Mar/2026
Moderna USD -1.39B 531M Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Novartis USD 4.18B 118M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Sanofi EUR 3.74B 2.23B Sep/2025
Takeda JPY -13.62B 271.11B Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Xencor USD -77.86M 24.23M Mar/2026